In the cumulative first quarter of the fiscal year ending March 2027, net sales\/ revenue reached 163,310 million yen (up 63.7% YoY), operating income 66,911 million yen (up 90.6% YoY), and net income attributable to owners of the parent 97,696 million yen (up 148.2% YoY), achieving a new high. Finance was significantly boosted by consolidation effects from the Edarabon business succession, the consolidation of Torii Pharmaceutical, and transactions related to the equity-method accounting for ViiV. Full-year guidance remains unchanged from the previous announcement. Cash decreased to 298,937 million yen. Main contributing factors include the consolidation of Torii Pharmaceutical, succession of the Edarabon business from\u7530\u8fba\u30d5\u30a1\u30fc\u30de (Tanabe Farm?), and related equity-method accounting for ViiV.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4507","jir_company_name":"Shionogi & Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-08-03","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/08\/4507-20260803-01.pdf","jir_short_summary":"In the cumulative first quarter of the fiscal year ending March 2027, net sales\/ revenue reached 163,310 million yen (up 63.7% YoY), operating income 66,911 million yen (up 90.6% YoY), and net income attributable to owners of the parent 97,696 million yen (up 148.2% YoY), achieving a new high. Finance was significantly boosted by consolidation effects from the Edarabon business succession, the consolidation of Torii Pharmaceutical, and transactions related to the equity-method accounting for ViiV. Full-year guidance remains unchanged from the previous announcement. Cash decreased to 298,937 million yen. Main contributing factors include the consolidation of Torii Pharmaceutical, succession of the Edarabon business from\u7530\u8fba\u30d5\u30a1\u30fc\u30de (Tanabe Farm?), and related equity-method accounting for ViiV.","jir_summary":"### Business performance overview\nFor the first quarter of the consolidated fiscal year, net sales were 163,310 million yen, up 63.7% from 99,781 million yen in the same period last year. Increases were driven by domestic pharmaceuticals and overseas subsidiaries\/export royalty income. The Edarabon business succession, the consolidation of Torii Pharmaceutical, and the application of equity-method accounting for ViiV Healthcare had significant effects on performance, with substantial increases in operating income, ordinary income, and net income attributable to owners of the parent. Cash on hand decreased. Full-year guidance remains unchanged from the previous announcement.\n\n### Outlook and impact\nThe earnings forecast for this year remains unchanged from the May 2026 release. Ongoing corporate actions, including the Edarabon business succession from Tanabe Pharma, the acquisition of Torii Pharmaceutical and succession of the JT Pharmaceutical business, and the acquisition of Akros\u2019 shares, are expected to continue impacting results. The accounting treatment for investments subject to the equity method and retrospective adjustments arising from provisional accounting could affect future figures.","jir_financial_highlights":"Net sales \/ revenue: 163,310 (YoY 63.7% increase)\nOperating income: 66,911 (YoY 90.6% increase)\nNet income attributable to owners of the parent: 97,696 (YoY 148.2% increase)\nCash and cash equivalents: 298,937 (vs prior quarter end -? (notes on increase\/decrease))\nFair value of acquired assets (Torii Pharmaceutical, JT Pharmaceutical business, Akros, etc.): To be detailed below (Provisional accounting adjustments finalized \/ retrospective adjustments)","jir_category":"","jir_hashtags":"#Shionogi, #FinancialInformation, #IR, #JapaneseStocks","jir_key_figures":"Net sales \/ revenue: 163,310 \u767e\u4e07\u5186\nOperating income: 66,911 \u767e\u4e07\u5186\nNet income attributable to owners of the parent: 97,696 \u767e\u4e07\u5186\nCash and cash equivalents: 298,937 \u767e\u4e07\u5186\nAcquired consideration (Torii Pharmaceutical, JT Pharmaceutical business, Akros, etc.) total: unknown (details described in the text)","jir_meta_title":"Shionogi Q1 Highlights and Outlook | April\u2013June 2026","jir_meta_description":"Shionogi Q1 FY2027 results. Net sales up 63.7% to 163,310 million yen; operating income 66,911 million yen; net income attributable to owners of the parent 97,696 million yen. Explains impacts from Torii Pharmaceutical and JT Pharmaceutical business consolidation.","jir_og_title":"Shionogi Q1 Highlights and Outlook","jir_og_description":"Shionogi Q1 FY2027 results. Substantial increases in sales and profits. Explains the impact of business combinations and whether full-year guidance changed.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":6919,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-93448","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n